Mi-RNA and COVID-19

Last updated: March 15, 2025
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

mi-RNA analysis

Clinical Study ID

NCT06881160
3155
  • Ages > 18
  • All Genders

Study Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19), induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease, characterized by respiratory failure, shock and multi-organ dysfunction requiring admission in the intensive care unit (ICU).

The aim of the present study is to analyze miRNAs associated with SARS-CoV-2 infection, disease severity and mortality.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • 18 years

  • diagnosis of SARS-CoV-2 infection confirmed by molecular testing on nasopharyngealswabs

Exclusion

Exclusion Criteria:

  • pregnant women

Study Design

Total Participants: 49
Treatment Group(s): 1
Primary Treatment: mi-RNA analysis
Phase:
Study Start date:
March 01, 2020
Estimated Completion Date:
December 01, 2027

Connect with a study center

  • Fondazione Policlinico Universitario A. Gemelli IRCCS

    Roma, RM 00167
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.